EUVIMEDEUVIMED entdecken
Crossref

Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural Sedation

Jason Arsanious, Angela Rowland, Michael J Sorich iD, Ashley M Hopkins, Sam Alfred, Andrew Rowland

The Journal of Clinical Pharmacology · 2025-05 · 65 (5) · 637-643

DOI: 10.1002/jcph.6171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 27.11.2024. Verfasst von Jason Arsanious und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Public Health, Flinders University, Adelaide, Australia. Hauptthemen laut MEDLINE: Midazolam, Ritonavir, Hypnotics and Sedatives. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Health and Medical Research Council, Cancer Council South Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intravenous midazolam is frequently used for procedural sedation. Use of ritonavir containing antivirals in patients requiring procedural sedation with intravenous midazolam is postulated to increase the risk or prolong the consequences of exposure related adverse events. The primary objective of this study was to characterize interaction of ritonavir with IV midazolam. The secondary objective was to define the time course over with the interaction of ritonavir with IV midazolam resolves following cessation of ritonavir. Physiologically based pharmacokinetic modeling was used to conduct clinical trials with a parallel group design defining exposure to a single 5 mg IV dose of midazolam in the presence and absence of nirmatrelvir/ritonavir dosed twice daily for 5 days. Simulations comprised 50 virtual healthy subjects aged 20 to 50 years (50% female). Based on FDA criteria, a moderate/strong interaction between nirmatrelvir/ritonavir and intravenous midazolam (area under the curve [AUC] ratio >2) was observed when intravenous midazolam was administered up to 72 h following cessation of nirmatrelvir/ritonavir. The geometric mean (90% CI) midazolam AUC ratio was 9.21 (5.44 to 16.43) when coadministered on the final day of nirmatrelvir/ritonavir dosing. Importantly, there was no change in peak exposure; the geometric mean (90% CI) midazolam maximum concentration ratio was 0.99 (0.99 to 1.00). Use of ritonavir containing antivirals is unlikely to increase a patient's risk of experiencing an exposure related adverse event following administration of intravenous midazolam but may prolong complications in patients who experience an event. A meaningful interaction persists for 72 h following cessation of nirmatrelvir/ritonavir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MidazolamRitonavirHypnotics and SedativesHumansAdultFemaleMaleMiddle AgedDrug InteractionsYoung AdultModels, BiologicalArea Under Curve

Stichwörter der Autor:innen

drug interactionmidazolamprocedural sedationritonavirtoxicity

Substanzen

MidazolamRitonavirHypnotics and Sedatives

Autor:innen und Institutionen

  • College of Medicine and Public Health, Flinders University, Adelaide, Australia.
  • SA Toxinology and Toxicology Service, Royal Adelaide Hospital, Adelaide, Australia.
  • Department of Emergency Medicine, Royal Adelaide Hospital, Adelaide, Australia.
  • Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia.

ORCID-Profile: Michael J Sorich

Förderung

  • National Health and Medical Research Council
  • Cancer Council South Australia

Zitieren

APA

Arsanious, J., Rowland, A., Sorich, M. J., Hopkins, A. M., Alfred, S., & Rowland, A. (2025). Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural Sedation. The Journal of Clinical Pharmacology, 65(5), 637-643. https://doi.org/10.1002/jcph.6171

Vancouver

Arsanious J, Rowland A, Sorich MJ, Hopkins AM, Alfred S, Rowland A. Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural Sedation. The Journal of Clinical Pharmacology. 2025;65(5):637-643. doi:10.1002/jcph.6171

BibTeX
@article{Arsanious2025,
  author = {Arsanious, Jason and Rowland, Angela and Sorich, Michael J and Hopkins, Ashley M and Alfred, Sam and Rowland, Andrew},
  title = {Ritonavir May Prolong Sedation but is Unlikely to Increase the Risk of Respiratory Arrest in Patients Requiring Intravenous Midazolam for Procedural Sedation},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  volume = {65},
  number = {5},
  pages = {637--643},
  doi = {10.1002/jcph.6171}
}
Kostenlos starten →